Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Change In Prescription Form Brings Changes To Japan’s Generic Drug Industry

This article was originally published in PharmAsia News

Executive Summary

The change in remuneration for medical services starting in April could greatly impact the generic drug industry in Japan. A new prescription form will provide that pharmacies can make substitutions unless a doctor specifically requests that a generic or substitution drug cannot be prescribed. Currently, substitutions are difficult except for some extreme situations. Pharmacies can substitute among various generic drugs, and procure from multiple brands thus reducing the need for surplus inventories. Branding will be vital for makers, along with price. Major players that have an enhanced product lineup may have a strong advantage. Foreign generic drug giants such as Teva, Sandoz, Mylan Laboratories and Lupin, which bought Osaka-based Kyowa Yakuhin last year, will be closely watched. (Click for more-Japanese language

You may also be interested in...



MHLW Reports Little Progress In Japan’s Generic Drug Use

Ministry of Health Labor and Welfare Minister Yoichiro Masuzoe and Treasury Minister Shoichi Nakagawa Dec. 18 announced a plan of reducing ¥220 billion in social insurance growth for fiscal year 2009, in which the real reduction will come from ¥23 billion as a result of generic drug use. However, a report released Dec. 15 by MHLW painted a discouraging picture of generic drug use in Japan, even amidst several pushes from the ministry to promote usage during the year.

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel